112 related articles for article (PubMed ID: 22236353)
21. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.
Pellin MA; Wouda RM; Robinson K; Tsimbas K; Kurzman ID; Biller BJ; Vail DM
Vet Comp Oncol; 2017 Sep; 15(3):919-931. PubMed ID: 27146577
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
Münster P; Marchion D; Bicaku E; Schmitt M; Lee JH; DeConti R; Simon G; Fishman M; Minton S; Garrett C; Chiappori A; Lush R; Sullivan D; Daud A
J Clin Oncol; 2007 May; 25(15):1979-85. PubMed ID: 17513804
[TBL] [Abstract][Full Text] [Related]
23. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
Papaldo P; Lopez M; Marolla P; Cortesi E; Antimi M; Terzoli E; Vici P; Barone C; Ferretti G; Di Cosimo S; Carlini P; Nisticò C; Conti F; Di Lauro L; Botti C; Di Filippo F; Fabi A; Giannarelli D; Calabresi F
J Clin Oncol; 2005 Oct; 23(28):6908-18. PubMed ID: 16129844
[TBL] [Abstract][Full Text] [Related]
24. Increased dosage of epirubicin and mitomycin-C for the treatment of metastatic adenocarcinoma of unknown primary site.
Polyzos A; Koulentianos E; Tzianoumis L; Sfikakis P
J Chemother; 1989 Jul; 1(4 Suppl):1185-6. PubMed ID: 16312826
[No Abstract] [Full Text] [Related]
25. [Results of clinical study with epirubicin hydrochloride injectable solution in hepatoma].
Monden M; Nakamura H; Yayoi E; Monden T; Ohi H; Arisawa J; Masuzawa M; Shimizu T; Tomono N; Seki K; Nakao N; Todo A; Inoue Y; Sakon M; Ohsaki Y; Hosoki T
Gan To Kagaku Ryoho; 1998 Sep; 25(11):1713-9. PubMed ID: 9757197
[TBL] [Abstract][Full Text] [Related]
26. Phase I-II trial of high-dose epirubicin in patients with lymphoma.
Case DC; Gams R; Ervin TJ; Boyd MA; Oldham FB
Cancer Res; 1987 Dec; 47(23):6393-6. PubMed ID: 3479245
[TBL] [Abstract][Full Text] [Related]
27. Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors.
Lübbe AS; Bergemann C; Riess H; Schriever F; Reichardt P; Possinger K; Matthias M; Dörken B; Herrmann F; Gürtler R; Hohenberger P; Haas N; Sohr R; Sander B; Lemke AJ; Ohlendorf D; Huhnt W; Huhn D
Cancer Res; 1996 Oct; 56(20):4686-93. PubMed ID: 8840985
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
Tjuljandin SA; Doig RG; Sobol MM; Watson DM; Sheridan WP; Morstyn G; Mihaly G; Green MD
Cancer Res; 1990 Aug; 50(16):5095-101. PubMed ID: 2379173
[TBL] [Abstract][Full Text] [Related]
29. Effect of a 1-hour IV infusion of doxorubicin on the development of cardiotoxicity in dogs as evaluated by electrocardiography and echocardiography.
Gillings S; Johnson J; Fulmer A; Hauck M
Vet Ther; 2009; 10(1-2):46-58. PubMed ID: 19742448
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model.
Vail DM; Chun R; Thamm DH; Garrett LD; Cooley AJ; Obradovich JE
Clin Cancer Res; 1998 Jun; 4(6):1567-71. PubMed ID: 9626479
[TBL] [Abstract][Full Text] [Related]
31. Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group.
Findlay BP; Walker-Dilks C
Cancer Prev Control; 1998 Jun; 2(3):140-6. PubMed ID: 10093625
[TBL] [Abstract][Full Text] [Related]
32. Weekly administration of low-dose doxorubicin for treatment of malignant lymphoma in dogs.
Ogilvie GK; Vail DM; Klein MK; Powers BE; Dickinson K
J Am Vet Med Assoc; 1991 May; 198(10):1762-4. PubMed ID: 2071476
[TBL] [Abstract][Full Text] [Related]
33. [Data on toxicity and individual therapy results on anti-neoplastic antibiotics in the dog].
Stein E
Tierarztl Prax; 1973; 1(4):445-56. PubMed ID: 4806282
[No Abstract] [Full Text] [Related]
34. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A
J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
[TBL] [Abstract][Full Text] [Related]
35. Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors.
Ogilvie GK; Richardson RC; Curtis CR; Withrow SJ; Reynolds HA; Norris AM; Henderson RA; Klausner JS; Fowler JD; McCaw D
J Am Vet Med Assoc; 1989 Dec; 195(11):1584-7. PubMed ID: 2599942
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of outcome associated with subcutaneous and intramuscular hemangiosarcoma treated with adjuvant doxorubicin in dogs: 21 cases (2001-2006).
Bulakowski EJ; Philibert JC; Siegel S; Clifford CA; Risbon R; Zivin K; Cronin KL
J Am Vet Med Assoc; 2008 Jul; 233(1):122-8. PubMed ID: 18593321
[TBL] [Abstract][Full Text] [Related]
37. Phase I-II study of epirubicin in multiple myeloma.
Case DC; Ervin TJ; Gams R; Sonneborn HL; Paul SD; Oldham FB
Cancer Res; 1988 Nov; 48(21):6246-8. PubMed ID: 3167870
[TBL] [Abstract][Full Text] [Related]
38. Comparison of two questionnaires to assess gastrointestinal toxicity in dogs and cats treated with chemotherapy*.
Malone EK; Rassnick KM; Bailey DB; Kiselow MA; Erb HN
Vet Comp Oncol; 2011 Sep; 9(3):225-31. PubMed ID: 21848625
[TBL] [Abstract][Full Text] [Related]
39. Supporting the veterinary cancer patient on chemotherapy: neutropenia and gastrointestinal toxicity.
Vail DM
Top Companion Anim Med; 2009 Aug; 24(3):122-9. PubMed ID: 19732730
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.
Warner E; Hedley D; Andrulis I; Myers R; Trudeau M; Warr D; Pritchard KI; Blackstein M; Goss PE; Franssen E; Roche K; Knight S; Webster S; Fraser RA; Oldfield S; Hill W; Kates R
Clin Cancer Res; 1998 Jun; 4(6):1451-7. PubMed ID: 9626462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
